Health Condition 1: J454- Moderate persistent asthma
Conditions
Interventions
Intervention1: Habb-e-Zeequn Nafas: Habb will be given orally, daily in a single dose of 53mg for 30 days.
Control Intervention1: Inhaler (Budesonide-formoterol DPI): Metered dose (mcg): 200/6 (1 inha
Sponsors
National Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age between 18-50 years. 2) All gender. 3) Bronchial asthma of mild (FEV1 more than 70%) to moderate severity (FEV1 60-69%) of predicted. 4) Patients ready to give consent for the study
Exclusion criteria
Exclusion criteria: 1) Patients below 18 and above 50 years of age. 2) FEV1 less than 60% of predicted in spirometry. 3) Patients with systemic illness such as HTN, IHD, DM, Thyroid disorders, etc. 4) Patients with a history of allergic rhinitis, emphysema, chronic bronchitis, pneumonia, pneumoconiosis, pulmonary tuberculosis. 5) Severe anemia. 6) Pregnant and lactating women. 7) Patients who had received corticosteroids, bronchodilators or CAM therapy within 2 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in FEV1, FEV1/FVC ratio, PEF assessed by SpirometryTimepoint: 0th, 15th, and 30th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Asthma Control Test scoreTimepoint: 0th, 15th,and 30th day | — |
Countries
India
Contacts
Public ContactProf Mohd Aleemuddin Quamri
National Institute of Unani Medicine
Outcome results
None listed